News

Everolimus treats patients aged 3 years and older who require therapeutic intervention but are not amenable to surgery. Everolimus targets mTOR, a protein that acts as a regulator

Sucampo will have exclusive commercial rights to any biologic products successfully developed and commercialized in the course of the collaboration. The agreement allows Numab to receive up to

The funding will be used in multiple animal efficacy studies as well as human safety studies to further demonstrate the utility of Anthim (ETI-204), to prevent disease and

The double-blind, dose-ranging, multi-center, parallel group, randomized study was designed to evaluate the safety and efficacy of taliglucerase alfa in 31 treatment-naive patients suffering from Gaucher disease. Patients

Currently, Huya’s novel anti-arrhythmic compound HBI-3000 is under development in both China and the US. Huya CTO and COO China Clement Gingras said the alliance with Zhejiang Chinese

The licensing deal covers a combination drug, using Zertane and another erectile dysfunction drug (PDE5 inhibitors and others), to simultaneously treat premature ejaculation and erectile dysfunction (ED). The

The trial aims to determine the tolerability, safety and pharmacokinetic profile of NKTR-181 upon repeat administration in preparation for Phase 2 clinical development in chronic pain patients. In

The trial aims to assess the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors. The company expects to recruit around 24 patients with final

Naeymi-Rad will succeed John Campbell, who co-founded the firm more than 14 years ago. Campbell Alliance was acquired by inVentiv Health in February 2011 and operates as inVentiv